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Background. Extraskeletal osteosarcoma (ESOS) is a rare subtype of osteosarcoma. We investigated patient characteristics, overall
survival, and prognostic factors in ESOS.Methods. We identified cases of high-grade osteosarcoma with known tissue of origin in
the Surveillance, Epidemiology, and End Results database from 1973 to 2009. Demographics were compared using univariate tests.
Overall survival was compared with log-rank tests and multivariate analysis using Cox proportional hazards methods. Results.
256/4,173 (6%) patients with high-grade osteosarcoma had ESOS. Patients with ESOS were older, were more likely to have an axial
tumor and regional lymph node involvement, and were female. Multivariate analysis showed ESOS to be favorable after controlling
for stage, age, tumor site, gender, and year of diagnosis [hazard ratio 0.75 (95%CI 0.62 to 0.90); 𝑝 = 0.002].There was an interaction
between age and tissue of origin such that older patients with ESOS had superior outcomes compared to older patients with skeletal
osteosarcoma. Adverse prognostic factors in ESOS included metastatic disease, larger tumor size, older age, and axial tumor site.
Conclusion. Patients with ESOS have distinct clinical features but similar prognostic factors compared to skeletal osteosarcoma.
Older patients with ESOS have superior outcomes compared to older patients with skeletal osteosarcoma.
1. Introduction
Extraskeletal osteosarcoma (ESOS) is a rare malignant soft
tissue sarcoma with histologic similarities to primary bone
osteosarcoma but without attachment to the bone or perios-
teum. ESOS accounts for 1% of all soft tissue sarcomas and
4% of osteogenic osteosarcomas [1]. Multiple case series
ranging from 10 to 88 patients have described this rare and
unique tumor, with distinct clinical features between ESOS
and primary bone osteosarcoma [2, 3].
ESOS is a tumor primarily of older age with amean age of
47.5 to 61 years [1].Themajority of case series describe a male
predominance [1, 3–7]. An early report described an overall
survival rate of 38% at 5 years [5]. However, more recent
groups that have used multiagent chemotherapy and wide
resection during surgical procedures have described overall
survival rates of 66 to 77%, similar to skeletal osteosarcoma
[7, 8]. Reported adverse prognostic factors includemetastatic
disease at presentation, large tumor size, and inability to
achieve complete surgical resection [1, 4, 5, 7, 9].
In order to further characterize this rare malignancy and
compare it statistically to primary skeletal osteosarcoma, we
used a large registry to analyze the largest known cohort of
patients with ESOS. We define patient and tumor character-
istics, estimated overall survival rates, and prognostic factors
specifically for patients with ESOS.
2. Methods
2.1. Patients. In this cohort study, the analytic cohort
included patients with osteosarcoma of skeletal or extraskele-
tal origin reported to the US National Cancer Insti-
tute’s SEER (Surveillance, Epidemiology, and End Results;
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http://seer.cancer.gov/data/) system from 1973 to 2009. This
registry captures clinical data and outcomes from approx-
imately one-quarter of the US population. Data are col-
lected from a variety of sources, including health providers,
pathology reports, laboratories, autopsy reports, and death
certificates. Standard data quality measures are employed.
We included a convenience sample of patients in SEER
with histologically confirmed high-grade osteosarcoma of
any age at time of diagnosis. Given their low metastatic
potential, we excluded patients with low-grade osteosar-
coma (e.g., parosteal and intraosseous subtypes). The SEER
database included 4,178 cases of high-grade osteosarcoma.
We excluded five patients with unknown tissue of origin,
which resulted in an analytic cohort of the remaining 4,173
patients.
2.2. Predictor Variable. We evaluated patient characteristics
and outcomes according to tissue of origin (skeletal versus
extraskeletal). Primary site was identified in SEER based on
ICD-O-3 topography codes, which was then used to code
each patient as having a skeletal or extraskeletal primary
tumor. As only tumors with the histology code for osteosar-
coma were included, primary tumors reported to arise in a
soft tissue site were defined as extraskeletal osteosarcoma.
Imaging materials (scans and/or scan reports) were not
available to confirm skeletal or extraskeletal tissue origin.
2.3. Outcome Variables. Patient characteristics and overall
survival were evaluated based on extraskeletal versus skeletal
disease. Analyzed variables included age at diagnosis (contin-
uous variable and age categorized in tertiles with exclusion of
the youngest patients, age≤ 17 years), sex, year of diagnosis (in
10-year increments), race, primary tumor location (evaluated
as distinct sites and also dichotomized with tumors of the
head, neck, and trunk defined as axial versus tumors of
the extremity defined as appendicular), presence of regional
lymphnodes, histologic subtype, tumor size (dichotomized at
10 cm), use of radiation therapy, and stage of disease, defined
as either localized or metastatic. Patients with only regional
node involvement outside of the primary site of disease were
determined to have localized disease.
To determine overall survival, we used total months of
follow-up and patient vital status at the time of last follow-up.
To determine competing events, we used the variables vital
status and cause-specific death, which describes death related
to cancer and noncancer causes.
2.4. Statistical Methods. We compared patient characteristics
between groups with skeletal osteosarcoma or ESOS using
chi-squared tests (for categorical variables) or Student’s t-
test (for continuous variables). Overall survival was estimated
using Kaplan-Meier (KM) methods with 95% confidence
intervals. Potential differences in overall survival between
groups were evaluated with log-rank tests. The median
follow-up time for the analytic cohort was 102 months.
We also performed competing risk analysis using the
Fine-Gray proportional subhazard model to focus on death
due to malignancy. Death due to causes other than osteosar-
coma was coded as a competing event. If cause of death
was unknown, then those patients were not included in the
competing risk analysis.
Cox proportional hazard methods were used to deter-
mine the effect of extraskeletal disease on overall survival
while controlling for other differences in patient character-
istics between the groups. Time dependent covariates were
used to test the proportional hazards assumption. The SEER
database was accessed using SEER∗Stat version 7.1.0.
3. Results
3.1. Patient Characteristics Differ between Extraskeletal and
Skeletal Osteosarcoma. Of the 4,173 patients in the analytic
cohort, 256 (6.1%) patients hadESOS. Table 1 provides patient
characteristics according to tissue of origin. The mean age
for patients with ESOS was 60.7 years compared to 31.4
years for those with skeletal osteosarcoma (𝑃 < 0.0001).
Patients with extraskeletal involvement were more likely
to be female (54.3% versus 44.5%, 𝑃 = 0.002), have an
axial tumor (61.1% versus 25.1%, 𝑃 < 0.0001), and have
regional lymph node involvement (7.7% versus 2.4%, 𝑃 <
0.0001). There was a statistically significant difference in
distribution in primary tumor sites (𝑃 < 0.0001), most
notable in comparing the frequency of primary tumors
arising in the lower extremity (32.7% for extraskeletal versus
62.6% for skeletal). Patients with extraskeletal tumors were
more likely to receive radiation treatment than patients with
skeletal tumors (25.3% versus 12.3%, 𝑃 < 0.0001). Whether
radiation was instituted prior to diagnosis of osteosarcoma
is unknown. About 30% of ESOS were found in the thorax,
which includes involvement of the chest wall, breast, heart,
and soft tissue. However, 6 cases were primary lung lesions, 4
were primary pleural lesions, and all are without documented
skeletal involvement. Almost all ESOS were reported to
have conventional osteosarcoma histology, rather than other
histologic subtypes of high-grade osteosarcoma. There were
no statistically significant differences in patient race, tumor
size, or stage of disease based upon tissue of origin.
3.2. Overall Survival Differs between Extraskeletal and Skeletal
Osteosarcoma. OnKaplan-Meier testing of the entire analytic
cohort, without accounting for competing risks, overall sur-
vival was inferior for patientswith ESOS as compared to those
with skeletal osteosarcoma (Figure 1(a)). The estimated five-
year overall survival for those with extraskeletal disease was
37% (95% CI 30.6 to 43.3) compared to 50.8% (95%CI 49.1 to
52.5; 𝑃 < 0.0001) for those with skeletal disease. Differential
overall survival was also seen according to tissue of origin
when looking exclusively at patients with localized disease,
but a statistically significant difference in overall survival
according to tissue of origin was not seen in the cohort
of patients with metastatic disease (see Supplemental Fig-
ure available online at http://dx.doi.org/10.1155/2014/902620).
Specifically, the estimated five-year overall survival for those
with localized extraskeletal disease was 47% (95% CI 39.8 to
54.6) compared to 63% (95%CI 60.8 to 64.7) for patients with
Sarcoma 3
0.00
0.25
0.50
0.75
1.00
Es
tim
at
ed
 o
ve
ra
ll 
su
rv
iv
al
3848 2932 2237 1855 1586 1384 1221 1077 931 833 729Skeletal
250 169 131 101 83 67 55 46 41 34 29Extraskeletal
Number at risk
0 12 24 36 48 60 72 84 96 108 120
Months from initial diagnosis
P < 0.0001
(a)
0.00
0.25
0.50
0.75
1.00
Es
tim
at
ed
 o
ve
ra
ll 
su
rv
iv
al
1653 1413 1124 933 803 710 632 558 475 425 375Skeletal
6 6 6 2 2 2 1 1 1 1 1Extraskeletal
Number at risk
0 12 24 36 48 60 72 84 96 108 120
Months from initial diagnosis
P = 0.32
(b)
0.00
0.25
0.50
0.75
1.00
Es
tim
at
ed
 o
ve
ra
ll 
su
rv
iv
al
820 698 555 473 410 368 325 292 254 224 199Skeletal
23 19 15 12 10 8 8 8 6 3 3Extraskeletal
Number at risk
0 12 24 36 48 60 72 84 96 108 120
Months from initial diagnosis
P = 0.908
(c)
0.00
0.25
0.50
0.75
1.00
Es
tim
at
ed
 o
ve
ra
ll 
su
rv
iv
al
740 559 406 340 294 243 208 179 159 144 118Skeletal
72 56 48 40 33 27 21 18 17 16 14Extraskeletal
Number at risk
0 12 24 36 48 60 72 84 96 108 120
Months from initial diagnosis
P = 0.320
(d)
0.00
0.25
0.50
0.75
1.00
Es
tim
at
ed
 o
ve
ra
ll 
su
rv
iv
al
635 262 152 109 79 63 56 48 43 40 37Skeletal
149 88 62 47 38 30 25 19 17 14 11Extraskeletal
Number at risk
0 12 24 36 48 60 72 84 96 108 120
Months from initial diagnosis
Extraskeletal
Skeletal
P < 0.0001
(e)
Figure 1: (a) Kaplan-Meier estimates of overall survival from the time of diagnosis according to tumor tissue of origin in all patients with
high-grade osteosarcoma [𝑛 = 4,173 (256 with extraskeletal involvement and 3,917 with skeletal involvement)]. (b) Kaplan-Meier estimates
of overall survival from the time of diagnosis according to tumor tissue of origin in patients aged from 0 to 17 years [𝑛 = 1,672 (6 with
extraskeletal involvement and 1,666 with skeletal involvement)]. (c) Kaplan-Meier estimates of overall survival from the time of diagnosis
according to tumor tissue of origin in patients aged from 18 to 32 years [𝑛 = 849 (24 with extraskeletal involvement and 825 with skeletal
involvement)]. (d) Kaplan-Meier estimates of overall survival from the time of diagnosis according to tumor tissue of origin in patients aged
from 33 to 59 years [𝑛 = 824 (72 with extraskeletal involvement and 752 with skeletal involvement)]. (e) Kaplan-Meier estimates of overall
survival from the time of diagnosis according to tumor tissue of origin in patients aged from 60 to 99 years [𝑛 = 828 (154 with extraskeletal
involvement and 674 with skeletal involvement)].
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Table 1: Characteristics of 4,173 patients with osteosarcoma according to tissue of origin.
Characteristic Skeletal osteosarcoma (𝑁 = 3,917) ESOS (𝑁 = 256) 𝑃 value
Mean age (range) 31.4 years
∗ 60.7 years∗∗
<0.0001
(0–99 years) (9–96 years)
Sex
Male 2,175 (55.5%) 117 (45.7%) 0.002
Female 1,742 (44.5%) 139 (54.3%)
Year of diagnosis
1973–1979 395 (10.1%) 9 (3.5%)
<0.00011980–1989 609 (15.5%) 21 (8.2%)
1990–1999 857 (21.9%) 64 (25%)
2000–2009 2,056 (52.5%) 162 (63.3%)
Race
Caucasian 3,031 (77.8%) 212 (82.8%)
0.232African American 536 (13.8%) 30 (11.7%)
Asian 297 (7.6%) 12 (4.7%)
Native American 32 (0.8%) 2 (0.8%)
Primary site
Lower extremity 2,392 (62.6%) 80 (32.7%)
<0.0001
Upper extremity 467 (12.2%) 18 (7.3%)
Head 398 (10.4%) 18 (7.3%)
Spine 114 (3%) 1 (0.4%)
Ribs/sternum 105 (2.8%) 0
Pelvis 343 (9%) 31 (12.7%)
Thorax 0 70 (28.6%)
Abdomen/retroperitoneum 0 27 (11%)
Primary tumor location
Axial 961 (25.1%) 154 (61.1%)
<0.0001
Appendicular 2,870 (74.9%) 98 (38.9%)
Regional lymph node
Present 61 (2.4%) 13 (7.7%)
<0.0001
Absent 2,519 (97.6%) 155 (92.3%)
Stage
Distant metastasis 794 (22.3%) 43 (18.6%) 0.188
No distant metastasis 2,763 (77.7%) 188 (81.4%)
Tumor size
<10 cm 1,252 (63.1%) 113 (58.9%) 0.241
≥10 cm 731 (36.9%) 79 (41.1%)
Radiation use
No 3,374 (87.7%) 186 (74.7%)
<0.0001
Yes 473 (12.3%) 63 (25.3%)
Histologic type
Osteosarcoma NOS 3,322 (84.8%) 239 (93.4%)
0.016
Fibroblastic OS 263 (6.7%) 10 (3.9%)
Telangiectatic OS 128 (3.3%) 3 (1.1%)
OS in Paget’s 79 (2%) 0
Small cell OS 30 (0.8%) 2 (0.8%)
Central OS 42 (1.1%) 1 (0.4%)
Periosteal OS 40 (1%) 0
High grade surface OS 13 (0.3%) 1 (0.4%)
OS: osteosarcoma; ESOS: extraskeletal osteosarcoma; NOS: not otherwise specified; totals for each variablemay vary due tomissing data but percentages reflect
the represented data.
∗Median age is 20 years. ∗∗Median age is 64 years.
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localized skeletal osteosarcoma (𝑃 < 0.0001). The estimated
five-year overall survival for those with metastatic ESOS was
10% (95% CI 2.7 to 23.3) compared to 19% (95% CI 16.4 to
22.4) for those with metastatic skeletal osteosarcoma (𝑃 =
0.137).
Due to the significantly older age of patients with ESOS,
we performed a competing risk analysis to account for death
due to other causes in the older population with extraskeletal
tumors. Once we controlled for competing events, there was
no difference in the cumulative incidence of death from
osteosarcoma between patients with extraskeletal or skeletal
disease.
Given that the majority of patients with ESOS were > 60
years of age, we compared overall survival of patients with
ESOS versus skeletal osteosarcoma categorized by tertiles of
age, with the youngest group (age ≤ 17 years) excluded due to
too few patients with extraskeletal disease in this group (𝑛 =
6; Figure 1(b)). We observed that the oldest group of patients
with osteosarcoma had inferior overall survival compared to
younger age groups (Figures 1(b)–1(e)). However, within this
older group, patients with ESOS had superior overall survival
compared to patientswith skeletal disease (Figure 1(e)).There
was no difference in overall survival based on tissue of origin
for the remaining two age tertiles (ages 18 to 32 and 33 to 59
years; Figures 1(c)-1(d)).
We constructed Cox proportional hazards models to
assess the impact of extraskeletal disease on overall survival
independent of potential confounders and again excluding
patients ≤ 17 years of age from the analysis. Covariates
included in our final model were tertiles of age and sex.
Metastatic status, decade of diagnosis, and primary site did
not satisfy the proportional hazard assumption; thus we
stratified on these covariates in our final model to control
for potential differences between groups. After controlling
for these variables, extraskeletal disease was predictive of
superior overall survival compared to skeletal disease (ref-
erence group). The hazard ratio for death for patients with
extraskeletal diseasewas 0.75 (95%CI 0.62 to 0.90;𝑃 = 0.002)
compared to patients with skeletal disease.
To better assess the interaction between age and impact
of extraskeletal disease on overall survival, we formally tested
for the presence of a statistical interaction by constructing a
Cox model of overall survival that included tertiles of age,
tissue of origin, and interaction term of these two variables.
The 𝑃 value associated with this interaction term was 0.043,
confirming a statistically significant interaction between the
age and the impact of tissue of origin on overall survival.
We next constructed a multivariate Cox model stratified by
age tertile in order to obtain tertile-specific estimates of the
hazard ratio for death in each tertile according to tissue of
origin. As above, thismodel also controlled for sex,metastatic
status, decade of diagnosis, and primary tumor site. We
observed that the hazard ratio for death associated with ESOS
compared to skeletal osteosarcoma decreased with increasing
tertile of age: 1.05 (95% CI 0.51–2.14) for 18–32 years of age;
0.97 (95% CI 0.69–1.37) for 33–59 years of age; and 0.65 (95%
CI 0.52–0.82) for 60–99 years of age.
Data on tumor size were not available in 48% of patients.
As such, this variable was omitted from the preceding
multivariate models but we used this variable to perform
a sensitivity analysis that was similar to the final model.
Covariates included in this sensitivity analysis were tertiles
of age, sex, tumor size, tumor site, and year of diagnosis.
Metastatic status did not satisfy the proportional hazard
assumption; thus we stratified on this variable. This model
yielded a similar estimate of the impact of extraskeletal origin
on overall survival compared to our preceding model that
did not include tumor size (hazard ratio of 0.79; 95% CI 0.63
to 0.99 for patients with extraskeletal disease compared to
patients with skeletal disease; 𝑃 = 0.039).
3.3. Prognostic Factors Predictive of Overall Survival in
Extraskeletal Osteosarcoma. We next evaluated potential
prognostic factors exclusively in the entire cohort of patients
with ESOS. On univariate analyses using Cox proportional
hazards methods, distant metastatic disease, larger tumor
(maximum diameter ≥ 10 cm), older age (age 60 to 99
years), axial tumor site, and regional node involvement were
all associated with statistically significantly inferior overall
survival (Table 2). Sex and year of diagnosis were not found to
be prognostic.We next performedmultivariate analysis using
Cox proportional hazards models to identify independent
adverse prognostic factors in this disease. We included the
following significant variables from the above univariate
analyses: metastatic status; tumor size; age; and tumor site.
Each of these variables remained prognostic on multivariate
analysis (Table 2).
Wenext evaluated potential prognostic factors exclusively
in patients with localized ESOS. On univariate analyses
using Cox proportional hazards methods, larger tumor size
(maximum diameter ≥ 10 cm), axial tumor site, and regional
node involvement were all associated with statistically sig-
nificantly inferior overall survival (Table 3). Age, sex, and
year of diagnosis were not found to be prognostic. We
next performedmultivariate analysis using Cox proportional
hazards models to identify independent adverse prognostic
factors in patients with localized ESOS. We included the
significant variables from the above univariate analyses and
both tumor size and axial tumor site remained prognostic on
multivariate analysis (Table 3).
Due to limited numbers of patients with data available
for both tumor size and regional node involvement, the
independent prognostic impact of regional node involvement
in this cohort was not assessed as this variable had the fewest
patients with available data in our cohort.
4. Discussion
In this study of ESOS, we observed that patients with ESOS
had significantly different clinical features from patients with
skeletal osteosarcoma, including older age, propensity for
axial tumors, and female preponderance. Although univari-
ate analysis demonstrated inferior overall survival for patients
with extraskeletal disease, once we controlled for competing
events, we found that patients with ESOS had a similar
cumulative incidence of death due to cancer as patients with
skeletal osteosarcoma. Multivariate analysis revealed for the
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Table 2: Univariate and multivariate prognostic factors for overall survival in a cohort of patients with extraskeletal osteosarcoma.
Univariate hazard ratio
(95% confidence interval) Univariate 𝑃 value
Multivariate hazard ratio
(95% confidence interval) Multivariate 𝑃 value
Distant metastasis 3.16(2.11–4.73) <0.0001
2.39
(1.34–4.25) 0.003
Tumor size ≥10 cm 2.03(1.40–2.95) <0.0001
2.11
(1.41–3.17) <0.0001
Axial tumor 1.98(1.39–2.80) <0.0001
1.65
(1.08–2.53) 0.021
Age
18–32 years
33–59 years
60–99 years
Reference
1.30 (0.63–2.70)
2.59 (1.31–5.12)
0.477
0.006
Reference
1.13 (0.45–2.79)
2.53 (1.08–5.90)
0.796
0.032
Regional lymph node
present
2.09
(1.14–3.83) 0.017 Not tested Not tested
Male gender 1.32(0.96–1.80) 0.086 Not tested Not tested
Year of diagnosis
1973–1979
1980–1989
1990–1999
2000–2009
1.80 (0.87–3.75)
0.80 (0.44–1.45)
0.85 (0.59–1.23)
Reference
0.115
0.465
0.390 Not tested Not tested
Table 3: Univariate and multivariate prognostic factors for overall survival in a cohort of patients with localized extraskeletal osteosarcoma.
Univariate hazard ratio
(95% confidence interval) Univariate 𝑃 value
Multivariate hazard ratio
(95% confidence interval) Multivariate 𝑃 value
Tumor size ≥10 cm 2.06(1.36–3.14) 0.001
2.36
(1.53–3.62) <0.0001
Axial tumor 2.04(1.35–3.07) 0.001
2.01
(1.30–3.11) 0.002
Age
18–32 years
33–59 years
60–99 years
Reference
1.28 (0.53–3.07)
2.26 (0.98–5.20)
0.580
0.055
Not tested Not tested
Regional lymph node
present
2.33
(1.23–4.41) 0.009 Not tested Not tested
Male gender 1.27(0.88–1.85) 0.204 Not tested Not tested
Year of diagnosis
1973–1979
1980–1989
1990–1999
2000–2009
1.39 (0.49–3.91)
0.69 (0.34–1.42)
0.99 (0.65–1.51)
Reference
0.537
0.316
0.964
Not tested Not tested
first time that extraskeletal disease was in fact favorable. This
effect was driven by an interaction between the age and
the impact of tissue of origin on overall survival, with the
majority of patients with ESOS being older and with ESOS
being favorable in older patients. Adverse prognostic factors
previously described for patients with skeletal osteosarcoma
were also shown to be prognostic among patients with ESOS.
As reported by other groups, patients with ESOS are
significantly older than patients with skeletal osteosarcoma
[1, 4–9]. Our cohort included only 6 patients with ESOS <
18 years/1672 (0.4%) patients < 18 years with osteosarcoma,
accounting for 2.3% of all patients with ESOS. In contrast
to previous reports, we observed a higher incidence of axial
primary tumors in patients with ESOS. Regional lymph
node involvement in osteosarcoma is a rare and unfavorable
finding previously reported by our group [10]. We observed a
female predominance for ESOS as did Choi et al., suggesting
that gender distribution varies in each cohort due to chance
[9]. Understanding the etiology for these clinical differences
will likely require greater understanding of the cell of origin
of ESOS. The increasing cases of osteosarcoma by year of
diagnosis reflect the expanding SEERdatabase in each decade
which resulted in more cases being captured and not an
increase in the incidence of disease.
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Previous literature prior to multimodal therapy reported
dismal overall survival for patients with ESOS, while recent
groups report similar overall survival with skeletal osteosar-
coma [3–9, 11]. Overall survival for our ESOS cohort was
inferior but controlling for competing events resulted in
similar incidence of death due to cancer. We also observed
that the oldest group of patients had the poorest survival, but
the presence of extraskeletal disease as compared to skeletal
disease renders a more favorable outcome specifically in this
age group that accounted for the majority of ESOS cases.This
finding could relate to differences in the biology of the tumor
with age or differential propensity to perform aggressive
surgical resection of soft tissue versus bone tumors in an older
population. Unfortunately, neither hypothesis is testable with
the data available in SEER. We note that radiation treatment
was more likely to be used in extraskeletal tumors, which
might suggest a lower rate of aggressive surgical resection
of these tumors, though this suggestion cannot be validated
in SEER. We also note that although 2% of the patients had
osteosarcoma in the setting of Paget’s disease, this is not a
high enoughproportion to account for the difference between
groups.
Among patients with ESOS, we found that distant
metastatic disease, larger tumor size (≥10 cm), axial tumor
site, and older age are adverse prognostic factors. In patients
with localized ESOS, axial tumor site and large tumor size
were adverse prognostic factors. We confirmed previous
reports that distant metastatic disease at diagnosis is an
unfavorable prognostic factor in ESOS [1]. Ahmad et al.
found that on univariate analysis there was a significant
difference in disease specific survival for tumor size >10 cm,
microscopically positive surgical margins, and TNM stage
>2 [4]. However, none of these factors remained significant
in multivariate analysis. In our larger analysis, we were able
to confirm the adverse prognostic impact of large tumor
size. Lee et al. found on univariate analysis that patients
with ESOS with chondroblastic subtype survived longer
than those with osteoblastic subtype [6]. Given the lack of
histologic heterogeneity of cases of ESOS in SEER, we were
not able to evaluate this finding. Goldstein-Jackson et al.
found that complete surgical resection was the only statisti-
cally significant prognostic factor in their univariate analysis
[7]. We note that data on surgical margin and extent of
surgical resection were not available for the current analysis,
though it seems reasonable to anticipate that these established
prognostic factors in osteosarcoma would likewise apply to
patients with ESOS.
Use of the SEER database has provided us with a large
cohort for this otherwise rare subgroup of osteosarcoma,
which has allowed us to analyze potential prognostic fac-
tors predictive of overall survival with greater power than
other smaller studies. Other strengths with this registry
include long-term patient follow-up and diverse population
as patients are registered from across the United States.
However, use of a registry has limitations, particularly with
regard to variables available for analysis. We recognize that
tumor size is an important clinical predictor and was only
available for 52% of our cohort. We were unable to perform
central review of imaging or pathology. In order to obtain
a large cohort with ESOS we captured patients over several
decades during which treatment has evolved.Wewere unable
to analyze overall survival based on treatment strategies
since use of chemotherapy and details on surgical procedure
(amputation versus limb sparing or presence of microscopic
margins) are either not provided or only sparsely provided in
SEER.We alsowere unable to determine the incidence of each
type of recurrence (local versus distant) to confirm previous
case series showing both high local and distant recurrent rates
[1, 4, 6]. We also did not have access to the percent tumor
necrosis after neoadjuvant chemotherapy, which is a known
prognostic factor in skeletal osteosarcoma but has not been
evaluated in ESOS thus far.
Our study reveals that the incidence of death from ESOS
is similar to skeletal osteosarcoma in this cohort of patients
and that overall survival varies by age such that the oldest
patients have more favorable outcomes with extraskeletal
disease as compared to skeletal osteosarcoma. Finally, fur-
ther prospective research is needed to understand if there
are biologic differences between extraskeletal and skeletal
osteosarcoma as these differences may explain the variation
in patient characteristics and overall survival between the two
groups.
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